[Nonketotic hyperglycemic coma induced by somatostatin in an AIDS patient].

Abstract

A 33-year-old woman with AIDS was treated with somatostatin (continuous infusion 6 mg/day) for intractable diarrhoea. Improvement was insufficient and the dose was increased to 12 mg/day 5 days later. Hyperosmolar non-ketotic coma occurred two days later (blood glucose 53 mmol/l, bicarbonate 8 mmol/l, pH of arterial blood 7.2). Search for urinary ketones was negative. Klebsiella pneumonia was isolated in the urine sample. Somatostatin was withdrawn and the patient improved with parenteral nutrition and intravenous insulin. Glucose tolerance was verified after recovery and was normal. Somatostatin is known to impair glucose tolerance and as shown in this case should also be recognized as a cause of hyperosmolar non-ketotic coma. Increasing use of somatostatin, particularly in HIV patients often given other hyperglycaemia inducing drugs such as didanosine, pentamidine, dapsone, and phenytoin should be accompanied with careful monitoring of blood glucose levels.

• Authors: B Vandercam, M P Hermans, P Coumans, D Jacques, J L Gala, J Kolanowski
• Journal: Presse medicale (Paris, France : 1983) (Presse Med) Vol. 24 Issue 30 Pg. 1389-90 (Oct 14 1995) ISSN: 0755-4982 [Print] France
• Vernacular Title: Coma hyperglycémique non cétosique induit par la somatostatine chez un patient atteint du SIDA.
• PMID: 8545317 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Hormone Antagonists
• Somatostatin

Topics

• AIDS-Related Opportunistic Infections (drug therapy, microbiology)
• Acquired Immunodeficiency Syndrome (complications)
• Adult
• Anti-Bacterial Agents
• Diarrhea (drug therapy, etiology)
• Drug Therapy, Combination (therapeutic use)
• Female
• Hormone Antagonists (administration & dosage, adverse effects, therapeutic use)
• Humans
• Hyperglycemic Hyperosmolar Nonketotic Coma (chemically induced)
• Klebsiella Infections (complications, drug therapy, microbiology)
• Somatostatin (administration & dosage, adverse effects, therapeutic use)
• Urinary Tract Infections (complications, drug therapy, microbiology)